Structured population data were available for 3 of 3 supporting studies. 1 study described adult participants.

2 relevant studies have unresolved authoritative design evidence and do not contribute to design-specific or RoB-specific claims.

Upstream consistency scoring indicates mixed findings across the evidence.

Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group, usual_care.

2 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

2 of 3 studies with duration data have follow-up of 12 weeks or less.

Self-Monitoring of Blood Glucose (SMBG)

Core clinician-reference fields are available or not applicable.

Participants received 50 days of continuous glucose monitoring.

Continuous Glucose Monitoring (CGM)

30 participants with chronic pancreatitis and insulin-treated diabetes were randomised to 50 days of CGM or SMBG, separated by a 20-day washout period.

Participants received 50 days of self-monitoring of blood glucose.

Authoritative quality diagnostic: sample size arm total mismatch.

CGM enhances glycaemic control in chronic pancreatitis diabetes.

Not extracted from the authoritative source.

Not applicable to this study design or comparison.

Source evidence could not be resolved sufficiently for this field.

Clinician-reference record is usable with limitations in: design, arms, risk_of_bias.

Authoritative quality diagnostic: invalid or missing unit.

Authoritative quality diagnostic: invalid or missing value.

Authoritative quality diagnostic: source evidence unresolved.

Community pharmacy-led diabetes management improves glycemic control in adults with T2DM

Usual diabetes care

Clinician-reference record is usable with limitations in: design, risk_of_bias.

Adults with type 1 or type 2 diabetes using Dexcom ONE CGM for 6 months.

Dexcom ONE CGM group

In this single-site prospective study, adults with type 1 (T1D) or type 2 diabetes (T2D) taking two or more insulin injections per day initiated Dexcom ONE CGM use and attended follow-up data collection visits after 3 and 6 months.

Participants received usual diabetes care during the study.

During the study, participants received usual diabetes care.

Continuous glucose monitoring × Time above range

Available supporting studies

CGM enhances glycaemic control in chronic pancreatitis diabetes.

Community pharmacy-led diabetes management improves glycemic control in adults with T2DM

Dexcom ONE use significantly reduces HbA1c in diabetes patients.